Rimonabant: A new class of drug to fight obesity

Indian Journal of Pharmacology

Volumn 38, Issue 3, 2006, Pages 220-221

  Singh, J ^a   Budhiraja, S ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CANNABINOID RECEPTOR ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROKININ 3 RECEPTOR ANTAGONIST; PLACEBO; RIMONABANT;

BINDING AFFINITY; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIZZINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; ENERGY EXPENDITURE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; INSULIN RESISTANCE; LIPOGENESIS; MEMORY; METABOLIC SYNDROME X; MOTOR ACTIVITY; NAUSEA; NONHUMAN; OBESITY; SHORT SURVEY; SMOKING; SMOKING CESSATION; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

EID: 33745143612     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.25821     Document Type: Short Survey

References (15)

1. Bray GA, Bounchard C, James WPT, editors. Handbook of Obesity. New York: Marcel Dekker; 1998.
2. Annual smoking attributable mortality, years of potential life lost, and economic costs. United States 1995-1999.
3. Iversen L. Cannabis and the brain. Brain 2003;126:1252-70.
4. Howlett AC, Barth F, Bonner TI. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202.
5. Compton DR, Aceto MD, Lowe J, Martin BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716): inhibition of delta-9-tetrahydro-cannabinol induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996;277:586-94.
6. Cota D, Marsicano G, Tschop M. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Inves 2003;112:423-31.
7. Coizet V, Cassel JC, Kelche C. Effects of the selective CB1 cannabinoid receptor antagonist, SR141716, on cognitive performance in intact, brain-damaged and scopolamine-treated rats. Behav Pharmacol 1998;9:25.
8. Wiley JL, Burston JJ, Leggett DC. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005;145:293-300.
9. Trillou CR, Arnone M, Delgorge C. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comjp Physiol 2003;284:345-53.
10. Heshmati HM, Caplain H, Bellisle F. SR141716, a selective cannabinoid CB1 receptor antagonist, reduces hunger, caloric intake, and body weight in overweight or obese men. Obes Res 2001;9:70.
11. Van Gaal L. RIO-Europe: A randomized, double-blind study of weight reducing effect and safety of rimonabant in obese patients with or without comorbidity. Program and abstracts from the European Society of Cardiology Congress 2004, Aug 28-Sep1; Munich, Germany; 2004.
12. Press release. [accessed 2004 Nov 9]. Available from: http://en.sanofi-aventis.com/press/p_press_2004.asp
13. Results from the RIO-North America trial show that first year improvements in cardiovascular risk factors are maintained in the second year of treatment. American Society of Cardiology Congress, 2004 Nov 9 (online). [accessed 2005 Feb 10]. Available from: http://www.sanofi-synthelabo.us/index. html
14. Boyd TS, Fremming BA. Rimonabant: a selective CB1 antagonist. Ann Pharmacother 2005;39:684-90.
15. Rinaldi-Carmona M, Barth F, Heaulme M. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995;56:1941-7.